Day: March 17, 2026

Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to Force an Ill-Timed Sale Process BETHLEHEM, Pa., March 17, 2026 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (“OraSure” and the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today issued the following statement in response to Altai Capital’s March 17, 2026, letter: OraSure’s Board and management team are steadfast in our commitment to driving value and acting in the best interests of all shareholders through disciplined execution and rigorous oversight. Rishi Bajaj, Altai’s...

FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) — Anbio Biotechnology (NASDAQ: NNNN) (“Anbio” or the “Company”), a global diagnostic company in in-vitro diagnostic (IVD) technologies, announced today that its CEO will participate in the upcoming KeyBanc Capital Markets Virtual Healthcare Forum on Wednesday, March 18, 2026. Anbio’s CEO is scheduled to participate in a fireside chat and will have the opportunity to share the Company’s previously disclosed business updates, strategic initiatives, and product development with the investor community. Anbio’s participation in the conference reflects the Company’s continued engagement with the investment community and supports its commitment to broadening access to rapid diagnostics, advancing its innovative product pipeline, and creating long-term value...

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will present the five-year overall survival (OS) from the KIMMTRAK (tebentafusp-tebn) Phase 3 trial in previously untreated HLA-A*02:01 positive patients with unresected or metastatic uveal melanoma (mUM), at the 2026 American Association for Cancer Research (AACR) Annual Meeting commencing on April 17, 2026. The Company will issue...

Two abstracts accepted for presentation One abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01 Another abstract on the use of Evaxion’s AI-Immunology™ platform in developing a personalized cancer vaccine strategy for glioblastoma (brain cancer) Evaxion will also participate in the AACR Oncology Industry Partnering event ahead of the annual meetingCOPENHAGEN, Denmark, March 17, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces two abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California, April 17-22, 2026. One abstract will include new biomarker and immunogenicity data for...

Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer Demonstration of Cyclin E1 protein overexpression as an indicator for poor prognosis in ovarian cancer patients with real world data SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, CA. “We are excited to highlight the potential to expand the opportunity for azenosertib as a combination therapy...

– Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways – NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical data on SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, will be presented in a poster session at the American Association for Cancer Research (AACR) taking place April 17-22 at San Diego Convention Center in San Diego, CA. The abstracts will be published in the online Proceedings of the AACR. Exposure of acute myeloid leukemia (AML) cell lines to increasing concentrations of SLS009 for 6 hours resulted...

SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present two preclinical posters at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22 in San Diego, California. Poster Presentation Details Title: Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alphaPoster/Abstract: 2950Session: Experimental and Molecular Therapeutics: Cellular Responses to Anticancer DrugsDate/Time: April 20, 2026, from 2:00-5:00pm PT / 5:00pm-8:00pm ET Title: Palazestrant, a CERAN, in combination with...

FREEHOLD, NJ, March 17, 2026 (GLOBE NEWSWIRE) — UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), a real estate investment trust (REIT) specializing in manufactured home communities, announced today that it has published its 2025 Annual Report. It is now available on the Company’s website at www.umh.reit. Samuel A. Landy, President and Chief Executive Officer, commented, “We are proud to announce that our 2025 Annual Report is now available on our website. We encourage everyone to read our Annual Report to gain further information on our Company and our future outlook.” UMH Properties, Inc., which was organized in 1968, is a public equity REIT that currently owns and operates 145 manufactured home communities, containing approximately 27,100 developed homesites, of which 11,000 contain rental homes, and over 1,000 self-storage...